These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23666159)

  • 1. Consecutive acquisition of time-resolved contrast-enhanced MR angiography and perfusion MR imaging with added dose of gadolinium-based contrast agent aids diagnosis of suspected brain metastasis.
    Tsuchiya K; Aoki S; Shimoji K; Mori H; Kunimatsu A
    Magn Reson Med Sci; 2013; 12(2):87-93. PubMed ID: 23666159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between two separate injections and a single injection of double-dose contrast medium for contrast-enhanced MR imaging of metastatic brain tumors.
    Ochi T; Taoka T; Matsuda R; Sakamoto M; Akashi T; Tamamoto T; Sugimoto T; Sakaguchi H; Hasegawa M; Nakase H; Kichikawa K
    Magn Reson Med Sci; 2014; 13(4):221-9. PubMed ID: 25167875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
    Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
    Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol.
    Runge VM; Wells JW; Nelson KL; Linville PM
    J Magn Reson Imaging; 1994; 4(5):669-73. PubMed ID: 7981511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
    Runge VM; Lee C; Iten AL; Williams NM
    Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
    Carvlin MJ; De Simone DN; Meeks MJ
    Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.
    Kuhn MJ; Hammer GM; Swenson LC; Youssef HT; Gleason TJ
    Comput Med Imaging Graph; 1994; 18(5):391-9. PubMed ID: 7954317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved vessel delineation in keyhole time-resolved contrast-enhanced MR angiography using a gadolinium doped flush.
    Beranek-Chiu J; Froehlich JM; Wentz KU; Doert AN; Zollikofer CL; Eckhardt BP
    J Magn Reson Imaging; 2009 May; 29(5):1147-53. PubMed ID: 19388120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
    Runge VM
    Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration].
    Renzetti P; Parodi RC; Losacco C; Rosso E; Arcuri T; Sardanelli F
    Radiol Med; 1999 Sep; 98(3):138-43. PubMed ID: 10575442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
    Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
    AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases.
    Yuh WT; Engelken JD; Muhonen MG; Mayr NA; Fisher DJ; Ehrhardt JC
    AJNR Am J Neuroradiol; 1992; 13(1):335-45. PubMed ID: 1595472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose gadoteridol in MR imaging of intracranial neoplasms.
    Runge VM; Kirsch JE; Burke VJ; Price AC; Nelson KL; Thomas GS; Dean BL; Lee C
    J Magn Reson Imaging; 1992; 2(1):9-18. PubMed ID: 1623287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Evaluation of Silent T1-Weighted MRI and Silent MR Angiography of the Brain.
    Holdsworth SJ; Macpherson SJ; Yeom KW; Wintermark M; Zaharchuk G
    AJR Am J Roentgenol; 2018 Feb; 210(2):404-411. PubMed ID: 29112472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis.
    Yuh WT; Tali ET; Nguyen HD; Simonson TM; Mayr NA; Fisher DJ
    AJNR Am J Neuroradiol; 1995 Feb; 16(2):373-80. PubMed ID: 7726087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium-DOTA enhanced MR imaging of intracranial lesions.
    Parizel PM; Degryse HR; Gheuens J; Martin JJ; Van Vyve M; De La Porte C; Selosse P; Van de Heyning P; De Schepper AM
    J Comput Assist Tomogr; 1989; 13(3):378-85. PubMed ID: 2723166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-dose gadolinium-enhanced MR imaging with magnetization transfer technique in brain tumors: comparison with conventional contrast-enhanced MR imaging.
    Han D; Chang KH; Han MH; Cho JY; Han SW; Kim HD; Seong SO
    AJR Am J Roentgenol; 1998 Jan; 170(1):189-93. PubMed ID: 9423630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Aug; 31(8):472-8. PubMed ID: 8854193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.